Acceleron is a biopharmaceutical company engaged in developing, manufacturing and commercializing novel biotherapeutics. Acceleron went public in September 2013 (NASDAQ: XLRN) and was then acquired by Merck (NYSE: MRK) in 2021.
Biotech
Healthcare
Details
- Founded
- 2003
- Partnered
- 2007
- Status
- Acquired
- Acquired by
- MERCK
- Ticker symbol
- NASDAQ: XLRN
Investors
Related News & Research
33 Total Posts
Article
Building biology-native data infrastructure for the AI era
As compute costs fall and models mature, sustaining a competitive edge in global drug development requires innovation across the entire data infrastructure stack. Biology-native data, agentic workflows, and lab automation will define the next generation of leading biotechs.
Roadmap
Roadmap: Reinventing life sciences with AI
As the global life sciences industry aims to manage costs and accelerate launches, AI is rewriting how services and software are delivered.
Roadmap
Roadmap: Transforming Indian healthcare, one specialty at a time
The shift towards single-speciality hospitals and clinics is becoming the preferred model in Indian healthcare, as insurance coverage has doubled in the past decade.